Published in Cancer Weekly, October 18th, 2005
The principal investigator for this study is Mario Boccadoro, MD, division of hematology, University of Turin, Italy.
The study is a phase I/II dose-escalating, multicenter, noncomparative, open-label study designed to assess the safety and the efficacy of Defibrotide with MPT regimen as a salvage treatment in advanced refractory MM patients. The phase I component of the study will combine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.